Erwan MORTIER

Directeur de Recherche CNRS
Responsable du groupe Mocka "Modulation of cytokines action" au sein de l'équipe 12 du CRCI²NA.
Directeur de la plateforme Imp@ct (Biogenouest, SFR-Santé)

FORMATIONS et DIPLÔMES OBTENUS
2021: Directeur de Recherche CNRS, section 27, Relations hôte-pathogène, immunologie, inflammation.
2017: Diplôme d’Habilitation à Diriger des Recherches. Université de Nantes.
2011: Diplôme d’Expérimentation Animale, Niveau I, ENVN ONIRIS, Nantes.
2010: Chargé de Recherche CNRS, section 27.
2005: Doctorat en Immunologie Université de Nantes.
2001: DEA Biologie - Santé (Université de Rennes)

ACTIVITÉS PROFESSIONNELLES
2021 - ... : Directeur de Recherche CNRS (CRCI²NA, Nantes)
2010 - 2021 : Chargé de Recherche CNRS (CRCINA, Nantes)
2009 - 2010 : Stage post-doctoral (CRCNA, Nantes)
2006 - 2009 : Stage post-doctoral, Cancer Research Institute Fellow (UCSF, San Francisco, USA, Prof. A. Ma)

ENSEIGNEMENT
2017 - ... : Master 2, Université de Rennes, « Cytokines, messagers du système immunitaire: exemple de l'interleukine-15» 1h30/an
2011 - ... : Master 2, Université de Nantes,  « Cytokines et Thérapie anti-cancéreuse» 1h30/an
2010 - ... : MSBM1, Université de Nantes, «Cytokines» 1h30/an

DIRECTION DE THESES
2018 - ... : Jimmy Smadja
2014 - 2017 : Marie Frutoso
2013 - 2016 : Dihia Meghnem
2010 - 2014 : Fella Tamzalit

1-     Mortier E., Maillasson M., Quéméner A. (2023) Counteracting Interleukin-15 to Elucidate Its Modes of Action in Physiology and Pathology. J. Interferon Cytokine Res. 43:2-22.
2-     Meghnem D, Maillasson M, Barbieux I, Morisseau S, Keita D, Jacques Y, Quéméner A, and Mortier E (2022) Selective targeting of IL-15Ra is sufficient to reduce inflammation. Front. Immunol. 13:886213.
3-    Smadja J, Quéméner A, Maillasson M, Sicard B, Leray A, Arzel L, Lebreton J, Mortier E, Dubreuil D, and Mathé-Allainmat M. (2021) Rational modification, synthesis and biological evaluation of N-substituted phthalazinone derivatives designed to target interleukine-15 protein. Bioorg. Med. Chem. 39:116161.
4-    Fiore P.F., Di Matteo S., Tumino N., Mariotti F.R., Pietra G., Ottonello S., Negrini S., Bottazzi B., Moretta L., Mortier E., and Azzarone B. (2020) Interleukin-15 and cancer: some solved and many unsolved questions. J. Immunother. Cancer. 8(2):e001428.
5-    Mortier E., Ma A., Malynn B.A., and Neurath M.F. (2020) Editorial: Modulating Cytokines as Treatment for Autoimmune Diseases and Cancer. Front. Immunol. 11:608636
6-   Quémémer A., Morisseau S., Sousa R.P., Trillet K., Maillasson M., Leray I., Jacques Y., Dion J., Barbieux I., Frutoso M., Laurent A.D., Le Questel J.-Y., and Mortier E. (2019) IL-15Rα membrane-anchorage either in cis or in trans is required for stabilization of IL-15 and optimal signaling. J. Cell. Sci. 133(5).
7-    Frutoso M, Morisseau S, Tamzalit F, Quéméner A, Meghnem D, Leray I, Jacques Y, Mortier E. (2018) Emergence of NK Cell Hyporesponsiveness after Two IL-15 Stimulation Cycles. J. Immunol. 201(2):493-506.
8-    Quéméner A., Maillasson M., Arzel L., Sicard B., Vomiandry R., Mortier E., Dubreuil D., Jacques Y., Lebreton J., Mathé-Allainmat M. (2017) Discovery of a Small-Molecule Inhibitor of Interleukin 15: Pharmacophore-Based Virtual Screening and Hit Optimization. J. Med. Chem. 60(14):6249-6272.
9-    Meghnem D., Morisseau S., Frutoso M., Trillet K., Maillasson M., Barbieux I., Khaddage S., Leray I., Hildinger M., Quéméner A., Jacques Y. and Mortier E. (2017) Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rb/gc Receptor. J. Immunol. 198(12):4563-4568.
10-    Tamzalit F., Barbieux I., Plet A., Heim J., Nedellec S., Morisseau S., Jacques Y., and Mortier E. (2014) IL-15-IL-15Rα complex shedding following transpresentation is essential for the survival of IL-15 responding NK and T cells. Proc. Natl. Acad. Sci. U S A. 10;111(23):8565.
11-    Mortier E., Advincula R., Kim L., Chmura S., Barrera J., Reizis B., Malynn B.A., and Ma A. (2009) Macrophage and dendritic cell derived IL−15Rα support distinct CD8+ T cell subsets. Immunity. 31:811.
12-    Mortier E., Woo T., Advincula R., Gozalo S., and Ma A. (2008) IL−15Ra chaperones IL−15 to the dendritic cells membrane complexes that activate NK cells via trans−presentation. J. Exp. Med. 205:1213.
13-    Mortier E., Quemener A., Vusio P., Lorenzen I., Boublik Y., Grötzinger J., Plet A. and Jacques Y. (2006) Soluble IL−15Rα Sushi as a Selective and Potent Agonist of IL−15 Action Through IL−15Rb/g: Hyper Agonist IL−15−IL−15Rα Fusion Proteins. J. Biol. Chem. 281:1612.
14-    Mortier E., Bernard J., Plet A., and Jacques Y. (2004) Natural, proteolytic release of a soluble form of human IL−15R alpha that behaves as a specific, high affinity interleukin−15 antagonist. J. Immunol. 173:1681.